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Abstract of the Dissertation

Computational analysis of genomic variants affecting predicted microRNA:target
interactions in prostate cancer
By Angélica Paola Hernández Pérez
Keck Graduate Institute of Applied Life Sciences: 2018

Prostate cancer (PCa) is the most common cancer of men in the United States and is third only to
lung and colon as a cause of cancer death. Clinical behavior of the disease is variable and the combination
of prostate-specific antigen (PSA) screening and Gleason score staging are currently the best available
molecular and pathology tools to predict outcomes. Cancer biology research establishes microRNAs
(miRNAs) as key molecular components in both normal and pathological states. Thus, elucidating miRNAs
perturbed by genomic alterations will expand our understanding of the molecular taxonomy of PCa with the
aim to complement current practices in the diagnosis, prognosis, and treatment of the disease. This study
reports the computational analysis of genomic variants affecting the seed sequence of five miRNAs,
changing the prediction of microRNA:target interactions in PC3, an androgen-independent cell line that
closely resembles prostatic small cell neuroendocrine carcinoma (SCNC). Genomic variants were detected
via deep-sequencing of PC3 and further computational work focused on mapping changes within the seed
sequence of predicted mature miRNAs. Five microRNA candidates (from now on denominated microRNA*)
with changes in the g2-g8 seed region were selected: miR-3161*-5p with rs35834266 G>insA; miR-3620*5p with rs2070960 C>T; miR-1178*-5p with rs7311975 T>G; miR-4804*-5pwith rs266435 C>G; and miR449c*-3p with rs35770269 A>T. Subsequently, the computational prediction of miRNA*:target interactions
revealed 643 new relationships. After functional enrichment analysis of new targets, seven genes were
associated with endocrine resistance (ABCB11, CDKN1B, NOTCH2, SHC4, CCND1, SP1, ADCY2) and
five genes with endocrine and other factor regulated calcium reabsorption (ATP1A2, ESR1, PRRKCB,
AP2B1, SLC8A1) categories. A gene-disease association literature search was performed for each of the
aforementioned genes in order to understand if they have been implicated in cancer, where CDKN1B,
NOTCH2, CCND1 have been reported to participate in prostate cancer progression. Microarray gene
expression analyses showed that few predicted microRNA* targets were underexpressed in untreated PC3
samples versus prostate epithelial cells from the GEO database. However, after assessing the frequency of
observed underexpressed genes per candidate microRNA* using a Fisher’s exact test, miR-4804*-5p target
genes (TNKS and GUCY1A3) were statistically significant. Next steps included the comparison between
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groups of genes subject to non-mutated microRNA and mutated microRNA* regulation using a KruskalWallis non-parametric test. Results were consistent with the microRNA-gene expression regulation model
despite the genomic variant in the seed region, nevertheless the effect of miR-3161*-5p, miR-3620*-5p,
miR-1178*-5p, miR-4804*-5p, and miR-449c*-3p cannot be predicted solely with the indirect experimental
approach that microarray gene expression platforms provide. For this reason, the assessment of recurrent
pairwise microRNA-mRNA expression associations was performed using CancerMiner, an online tool from
The Cancer Genome Atlas (TCGA) based on a multivariate linear model and rank transformations. Only the
relationship of miRNA-3161:CDKN1B was retrieved as a recurrent expression association in uterine corpus
Kip1

endometrial carcinoma (UCEC). In the context of this study, results suggest that CDKN1B (p27

)

dysregulation by miR-3161*-5p would be leading to PC3 super proliferation due to the lack of cell cycle
arrest from phase G1 to S. Prostate cancer cell line PC3 has shown to share features with prostatic small
cell neuroendocrine carcinomas (SCNC) with the implication that molecular mechanisms and therapeutic
1

efficacies observed with PC3 cells are likely applicable to SCNC . Prostatic small cell neuroendocrine
carcinoma is a variant form of prostate cancer often characterized by an aggressive course with a poor
response to conventional androgen deprivation therapy (ADT), consistent with the lack of the androgen
2

receptor in prostatic small cell carcinoma (SCC) . In some men treated with ADT, development of small cell
carcinoma might represent the “escape” of a subpopulation of hormone-independent cells resulting from the
3

selective pressure of hormonal therapy . Hence, the suggestion of CDKN1B dysregulation by miR-3161*-5p
might go beyond the idiosyncrasy of the PC3 cell line, but rather an interesting future direction to investigate
prostate cancer patients with SCNC rendering to an adverse disease outcome due to uncontrolled cell
proliferation.
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Chapter 1 – Organization of the Thesis
Context of Study
Prostate cancer is the most common cancer among men in the United States and is third
only to lung and colon as a cause of cancer death. In 2017, an estimated 161,360 new cases of
prostate cancer were newly diagnosed while 26,730 people succumbed to this disease4. Multiple
genetic and demographic factors, including age, family history, genetic susceptibility, and race,
contribute to the high incidence of prostate cancer4. Clinical behavior of the disease varies from
treating localized tumors with surgery, radiation, and initial hormone therapy to other more
aggressive metastasis stages that do not respond to previous hormone treatments5. The
combination of clinical assessments and pathological parameters such as prostate-specific
antigen (PSA) screening and Gleason score staging are currently the best available tools to
predict outcomes6.
Despite advances in therapy options, the diagnostic landscape has remained relatively
static due to poor specificity and sensitivity of screening tools. This results in the over diagnosis of
the disease’s early-stages and the overtreatment of benign conditions7. Hence, there is an urgent
need for novel biomarkers to develop alternatives to address these clinical challenges. One of
these alternatives are microRNAs, which are small non-coding RNA ~19-25 nucleotides in length
that regulate gene expression at the post-transcriptional level8. Since the discovery of hundreds of
microRNAs in mammals, research on microRNAs has focused on providing evidence in favor of
their involvement in normal and diseased conditions. In particular, there has been a community
effort to understand their functional implication in the pathogenesis of cancer9,10. Thus, elucidating
the use of microRNAs as candidate biomarkers can further complement current practices in the
diagnosis and prognosis of prostate cancer.
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Statement of Problem
The emergence of microRNAs in cancer biology has established them as key molecular
components in both normal and pathological states9,11. The literature on microRNAs has
remarkably expanded, with research ranging from assessing the effects of a single microRNA
perturbation to understand tumor growth and invasion12,13, up to systemic genome-scale
reconstructions of cancer hallmarks that include the expression of microRNA signatures14–16.
microRNA molecules work as guides to the RNA-induced silencing complex in mRNA
destabilization and translational inhibition pathways17–21. Once the RNA-induced silencing
complex (RISC) is assembled, the Argonaute (Ago) protein binds the mature microRNA which
guides the target-recognition process to one or more mRNAs8,22,23. microRNAs bind through direct
base pairing to potential target sites, prominently in the 3′ untranslated region (3′-UTR) of the
mRNA24,25. A core of 6 nucleotides extending from position 2 to 8 (g2-g8) at the 5′ end of the
microRNA, termed as the seed sequence, are the most critical for initial target binding26,27.
The importance of microRNAs in cancer has been emphasized by the identification of
genetic alterations affecting microRNA target sites and the microRNA processing machinery in
tumor cells28,29. However, it is equally important to understand the effect of genetic variants
mapping within the seed sequence of microRNAs. A focus on the gain and loss of
microRNA:mRNA interactions due to these variants, especially in the g2-g8 location, is essential
to help predicting how a small genetic change can influence target recognition, binding, and the
regulation of gene expression profiles in oncogenic events.

Aim and Scope
The aim of this study is to computationally predict the loss and gain of microRNA:mRNA
interactions due to variants mapping in the seed sequence of microRNAs (miRNA*) in prostate
cancer cell line PC3. The scope of this research is limited to variations in the g2-g8 seed
sequence positions associated to functional implications of microRNA fine-tuning of mRNA. This
assessment is done in the context of prostate cancer cell line PC3, which closely resembles
2

prostatic small cell neuroendocrine carcinoma (SCNC), a variant form of prostate cancer that is
extremely aggressive and does not respond to hormonal therapy1,30.

Significance of the Study
The central hypothesis of the present thesis is that a genomic variant mapping within the
seed sequence of a microRNA will have an effect on the recognition of microRNA-binding sites
thus gaining or losing microRNA:target interactions. If the microRNA:target interaction is lost, the
former target gene is expected to be upregulated. If a new microRN:target interaction is gained,
the new predicted target gene is expected to be downregulated. This study systematically
describes the computational identification of a set of affected microRNAs in the g2-g8 seed
sequence region that gain interactions with genes associated with endocrine resistance and
reported to be underexpressed in the context of cancer. Results indicate that miR-3161*-5p (with
a rs35834266 G>insA in the seed region) might lead to CDKN1B dysregulation, leading to cell
cycle arrest from phase G1 to S thus creating PC3 proliferation. Molecular mechanisms and
therapeutic efficacies observed with PC3 cells are likely applicable to small cell neuroendocrine
carcinoma (SCNC), a variant form of prostate cancer often characterized by an aggressive course
with a poor response to conventional androgen deprivation therapy (ADT). The suggestion of
CDKN1B dysregulation by miR-3161*-5p might go beyond the idiosyncrasy of the PC3 cell line,
but rather an interesting future direction to investigate prostate cancer patients with small cell
neuroendocrine carcinoma rendering to an adverse disease outcome due to uncontrolled cell
proliferation.

Overview
This thesis is arranged into five chapters. Chapter 1 contains the introduction
encompassing the context, statement of the problem, aim and scope, as well as the significance
of the study to guide the reader on a concise, clear and logical structure of the material. Chapter 2
includes the literature background of the clinical assessment of prostate cancer, the current status
3

of microRNA, and the description of the interplay of microRNA, genomic variants, and prostate
cancer. Chapter 3 is a breakdown of the research approach and the description of the
computational methods used to fulfill the stated aim of this study. Chapter 4 is the presentation of
results. Chapter 5 is the discussion of the study’s results and explores possible future research
directions. This project has been in collaboration with the Sanford Burnham Prebys Medical
Discovery Institute (Lake Nona, Florida), and the Human Systems Biology Laboratory at the
Instituto Nacional de Medicina Genómica (CDMX, México).
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Chapter 2 – Background
Clinical Assessment of Prostate Cancer
Prostate cancer is the most common cancer among men in the United States and is third
only to lung and colon as a cause of cancer death. In 2017, an estimated 161,360 new cases of
prostate cancer were newly diagnosed while 26,730 people succumbed to this disease4. Prostate
cancer mostly affects men in the range of 60 to 80 years old and considering that the worldwide
trend is a higher number of aging populations, the disease is predicted to significantly increase in
the next decade31,32.
Multiple genetic and demographic factors, including age, family history, genetic
susceptibility, and race, contribute to the incidence of prostate cancer4. Almost 60% of the
diagnosed cases are in men 65 years old33 in average, and the United States the disease is
especially frequent in men of African origin, as incidence rates in African Americans are >1.5–fold
greater than rates in European Americans34. Prostate cancer presents the greatest racial disparity
of any cancer in the U.S., and research suggests that environmental influences such as diet and
nutrition may have a profound effect on the development and progression of histological cancer to
a clinically detectable cancer35,36.
The prostate is a walnut-shaped organ that contributes fluid to semen and helps expel
semen during ejaculation. Because the prostate lies below the bladder and surrounds the urethra,
most prostate cancer signs are tied to urinary disfunction33, similar to lower urinary tract
symptoms (LUTS)37, with a combination of weight loss, bone pain, and lethargy31. In general, the
earlier the disease is detected, the better the outlook for treatment and arresting cancer
progression in patients. Besides the advances, we have to be aware of the risks and adverse
effects on the quality of life related to the over-diagnosis and immediate treatment of benign
conditions such as prostatitis, inflammation of the prostate and benign prostatic hyperplasia
(BPH), a noncancerous enlargement of the prostate gland38,39.
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Most prostate cancer suspects are identified via digital rectal examination (DRE)40 (Figure
1) and by raised-levels of prostate specific antigen (PSA). PSA is a glycoprotein secreted by the
epithelial cells of the prostate gland, and it is produced to liquefy semen allowing sperm to swim
freely. It is expressed in both normal and neoplastic prostate tissues, thus elevated levels of PSA
are not specific for malignancy and can be found in conditions such like BPH41,42, prostatitis38, and
urinary tract infections40. Approximately 25% of men with PSA levels above 4 ng/mL are
diagnosed with prostate cancer, and the risk increases to more than 60% in men with PSA levels
above 10 ng/mL31. Limitations of PSA screening are well known43–45 and controversies on its
clinical utility are mostly about the “one test, several roles” screening practice. PSA can be used
during early detection, risk stratification and staging, as well as in post-treatment monitoring.
Thus, recommendations on when and how to use it are beyond our scope and can be reviewed
elsewhere46,47.

Figure 1 Digital rectal examination (DRE) is performed by feeling the posterior portion of the gland
(peripheral zone) provided that the tumor is sufficiently large to be palpable. Once the tumor metastasizes
and migrates to other tissues, biopsies and imaging techniques become resources to locate other tumors
31
with prostate cancer etiology. Image used and modified from Kirby, R. S. and Patel, M. I.

The combination of age-specific PSA, along with pathological findings (Gleason score
staging) are currently the best available tools for prognosis and to assess potential treatments for
the disease6,48,49. Clinical behavior of prostate cancer is variable, with patients having localized
tumors that can be treated with radiation therapy (external beam or brachytherapy), several
months of hormone therapy, and active surveillance4,33,46. The ability to treat many others with
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aggressive stages that include bone metastasis and resistance to previous hormone treatments is
limited5,50.
Androgens and androgen receptor (AR) signaling are necessary for prostate development
and homeostasis. AR signaling also drives the growth of nearly all prostate cancer cells. The role
of androgens and AR signaling has been well characterized in metastatic prostate cancer, where
it has been shown that prostate cancer cells are exquisitely adept at maintaining functional AR
signaling to drive cancer growth51. Current strategies to restrict its activity are via androgen
deprivation therapy (ADT), a standard of care for men with advanced metastatic and recurrent
prostate cancer. Dihydrotestosterone (DHT), or 5α-dihydrotestosterone (5α-DHT), is an
endogenous androgen sex steroid and hormone essential for normal prostate growth which also
plays a role in the development of the disease52–54. ADT acts by blocking DHT and stopping
cancer progression with substantial clinical response in conjunction with surgery or radiation55.
However, ADT becomes less effective over time and does not work in patients with castrationresistant prostate cancer (CRPC)56, in which AR is frequently reactivated in the absence of
androgens. During intense antiandrogen therapy, a small percentage of men develop treatmentemergent AR-negative small cell/neuroendocrine prostate cancer (SCNC)57, a highly aggressive,
androgen-independent PCa type that does not respond to ADT at all58. Resistance to hormone
therapies is a major challenge in PCa creating the need for new prognostic biomarkers and
consequently therapeutics targeting signaling pathways that directly or indirectly affect hormone
driven gene expression regulation in different levels of the signaling pathways.

Genomic Variants in Prostate Cancer
The biological basis of inherited and acquired genetic variants associated with prostate
cancer has been studied by several research consortia utilizing genome-wide association studies
(GWAS)34,59, exome sequencing60, and candidate gene studies61 (Fig 2). Genetic variants that
predispose an individual to a particular disease can be attributable to genetic mutations that are
rare but highly penetrant, or genetic variants that confer moderate-to-low risk for developing the
7

disease, or a combination of these factors62. Early studies in prostate cancer genetics focused on
identifying high-risk loci because these were deemed to have obvious clinical usefulness in terms
of identifying a direct causal effect for this disease in individuals, and were easier to identify with
existing technologies, like gene expression microarrays63.

Figure 2 Summary of research strategies currently employed by the associated consortia to evaluate the
clinical utility of prostate cancer susceptibility loci. In addition, The Cancer Genome Atlas (TCGA) and The
International Cancer Genome Consortium (ICGC) are the two main consortia providing cancer genomics
information related to fifty different cancer types, including prostate cancer (PRAD projects). Image used
62
and modified from C.L. Goh et al .

Next-generation sequencing (NGS) offers the advantage to identify variants already
annotated and to discover new variants present in the NGS sample of diagnostic interest. Various
8

published studies using this platform have explored the molecular basis of prostate cancer during
the clinical progression of the disease using profiled tumors and model cell lines63–65. Reports
include multiple recurrent genomic alterations like somatic point mutations, DNA copy-number
changes, gene fusions, epigenetic and transcriptomic pathway alterations66,67. One NGS tumor
sample gives us millions of potentially biologically relevant variables, reminding us that tumor
genomics is far more complex and heterogeneous than expected.
The vast majority of our knowledge about cancer genomics comes from the two largest
cancer-sequencing consortia, The Cancer Genome Atlas (TCGA) and The International Cancer
Genome Consortium (ICGC). The aim of both consortia is to completely sequence the genomes
of the 50 most important tumor entities. In regards of prostate cancer, The Cancer Genome Atlas
reported a comprehensive molecular analysis of 333 primary prostate carcinomas showing seven
major genomic subtypes defined by ETS gene fusions (ERG, ETV1/4, and FLI1) or mutations in
SPOP, FOXA1, and IDH1 genes. Also, the authors revealed potentially therapeutically actionable
lesions in the phosphatidylinositol 3-kinase, mitogen activated protein kinase, and DNA repair
genes that are valuable for clinical management67. Of high clinical relevance is that each
molecular subgroup is defined by a single distinct molecular alteration such as gene fusions or
mutations which sets the expectation for a molecular re-classification of prostate cancer.
Despite some evidence of disease-associated coding single nucleotide polymorphisms
(SNPs)68, the molecular basis of how the majority of the prostate-cancer-associated SNPs
function is largely unknown because most are noncoding, lying in intronic or intergenic regions.
These SNPs might exert their influence by mapping in regions responsible for fine-tuning
regulation of gene expression. Other postulated mechanisms of action include structural
rearrangements and changes in DNA structure 23,66, and RNA structure69.
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What is a microRNA?
microRNAs are small non-coding RNAs ~19-25 nucleotides in length that regulate gene
expression at the post-transcriptional level8. The biogenesis of animal microRNA is a multistep
coordinated process, in which structural and sequential prerequisites are needed for the correct
expression of mature microRNA70. MicroRNAs are transcribed by RNA polymerase II, resulting in
a primary microRNA (pri-miRNA) transcript that is processed by cleavage in the nucleus by a
complex involving Drosha and DGCR8 microprocessor complex subunit (DGCR8)71. This step
forms the precursor microRNA (pre-miRNA) stem loop structure where the 5p strand is present in
the forward (5'-3') position and the 3p strand (which will be almost complimentary to the 5p strand)
is located in the reverse position.
This pre-miRNA is exported into the cytoplasm by exportin-572,73 (XPO5) where it is
cleaved by Dicer, the RNase that is found in a multiprotein complex along with the transactivation-responsive RNA-binding protein (TRBP). In this stage, mature microRNA sequences
are formed in a duplex and one strand is incorporated into the RNA-induced silencing complex
(RISC)9 by loading to the Argonaute (AGO1-4) protein (Fig 3). The mature microRNA guides the
target-recognition process to one or more mRNAs8,74. This step causes the mRNA to be more
rapidly degraded or leads to inefficient protein production by reducing protein output75.
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Figure 3 Overview of microRNA biogenesis pathway leading to mRNA destabilization and translational
repression. In terms of which strand is functional following Dicer cleavage of the stem loop to produce the
two mature strands, either the 5p or 3p strand could be functional. The stability of the mature strand may
influence its function and ability to enter the RISC complex to then bind to its target gene. In general, the
more stable strand will be functional, and the less stable strand will be degraded. In some cases, even both
76
74
strands could be functional . Image redrawn and modified from Shuibin Lin and Richard I. Gregory .

Understanding the basics of microRNA:mRNA binding mechanisms and its dependence
on sequence complementarity is crucial to assess the biological and functional implications in
gene expression at the post-transcriptional level. It is well established that microRNAs load on
Argonaute proteins77–80 (in human, AGO2) and are further organized into even smaller segments
with thermodynamic81–83 and kinetic properties84–90 more typical of RNA-binding proteins than of
nucleic acids27,79. MicroRNAs bind through direct base pairing to potential target sites prominently
in the 3′ untranslated region (3′-UTR) of the mRNA. A core of 6 nucleotides extending from
position 2 to 8 at the 5′ end of the microRNA, termed as the seed sequence, are the most critical
for initial target binding26,27.
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Biochemical and computational analyses of preferentially conserved animal microRNAs
have revealed how miRNA-pairing motifs interact leading to the identification of several classes of
target sites8. In the first group, which includes most biologically functional microRNA:target
interactions, microRNAs bind to their targets only through their seed regions (the canonical
binding). This group can be subdivided into three seed-matching classes: (a) 7mer-A1 site, with
sequence complementarity over positions g2-g7 in the guide, plus an A at position 1 on the
corresponding sequence on the target mRNA (termed t1); (b) 7mer-m8 site, with sequence
complementarity over positions g2–g8; and (c) 8mer site, with sequence complementarity at
positions g2–g8 plus an A at t1 (Fig 4).
In the second group, less typical seed matches (the marginal sites) are enclosed: (a) 6mer
site, with complementarity at positions g2–g7 but lacking an A at t1; (b) offset 6mer site, with
complementarity at positions g3–g8. Whereas most microRNAs bind their targets either
canonically or marginally, there exists a third group much less numerous of microRNA:target
configuration in which RISC extends the base pairing beyond the seed-match. This type of pairing
(atypical sites) either supplements the 6, 7, or 8mer sites described above, or complements for
mismatches in the seed region8,91.
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g1-g8

g1g1-g8

g1-g8

Figure 4 microRNA seed sequence categorization and canonical binding sites in the 3'-UTR in mRNA.
Most functional microRNAs fall within this categorization. Vertical dashes indicate contiguous Watson–Crick
pairing. The probability of conserved targeting and predicted structural accessibility are considered two of
the main targeting features in target prediction models such as context++. Image used and modified from
8
David Bartel .

In mammals, Argonaute organizes the guide RNA geometry in a way that positions g2–g7
are in pre-helical form creating a unique configuration that determines whether RISC simply binds,
or both binds and cleaves26,27,87,88. Argonaute assigns greater value to mismatches before position
g5 than from g5–g8. Pairing of g2–g5 with a target appears to be ‘‘all or none,’’ with both central
and terminal dinucleotide mismatches disrupting binding to a similar extent (Figure 5). Notably,
the structure of human AGO2-RISC bound to a seed-matched target suggests that pairing beyond
g5 requires a conformational rearrangement in the protein27,79.
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Figure 5 Kinetic model for AGO2-RISC function and the impact on target binding. Argonaute assigns
greater value to mismatches before position g5 than from g5–g8. TargetScanHuman v7.1 includes
predicted seed-pairing stability in the context++ ruled-based algorithm and other fourteen targeting features
91
(Agarwal et al 2015 ) that make this approach at least as predictive as the most in vivo cross linking
79
approaches such as PAR-CLIP and HITS-CLIP. Image used and modified from William E. E. Salomon .

Accurate target prediction remains a challenge. Most computational approaches are based
on indirect measurements of microRNA and mRNA expression fold changes that are irrelevant to
the mechanism of targeting92–94. Although numerous advances have been made95,96, only
TargetScanHuman v7.1 has developed an improved quantitative model (context++) of targeting
efficacy using a compendium of 74 experimental datasets pre-processed to minimize confounding
biases91. The model uses a stepwise regression to identify the most informative features from a
large set of potential targeting features91 (Figure 6). This approach allows context++ to be more
predictive than any other published model and at least as predictive as the most informative in
vivo crosslinking approaches, such as PAR-CLIP and HITS-CLIP97.

14

Figure 6 Context++ algorithm diagram describing the score features of microRNA, score features of sites,
and score features of microRNA families taken into consideration to calculate the context++ score for each
microRNA binding site and summary of microRNA:target predictions. Image used from Vikram Agarwal et
91
al .

MicroRNA, Genomic Variants, and Prostate Cancer
Nearly every microRNA has been associated with abnormal gene expression changes in
cancer versus normal cells98–100. microRNAs may serve as tumor suppressors, oncogenes, and as
housekeeping regulators working as locks or switches when found as signatures9. Most of them
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are encoded in clusters and work as cooperative functional units with a tendency to target the
same gene or different genes in the same pathways22. Tissue-specific and stage-specific changes
in microRNA targeting are reported to be driven to equilibrate dominant oncogenic signaling
pathways active in prostate cancer97. Evidence suggests that microRNAs, even in advanced
prostate cancer, adapt to regulate continuing alterations to balance oncogenic molecular
changes101–103.
As any other gene, microRNAs loci are exposed to mutations, amplifications, deletions
and genomic translocations. These changes could trigger aberrant expressions of microRNA
genes and consequently the dysregulation of target mRNAs11. Other indirect causes of
dysregulation have been emphasized by the identification of genetic alterations affecting
microRNA target sites23 and the microRNA processing machinery in tumor cells28,29 such as
Drosha104,105 and Dicer106. Understanding genomic alterations in regulatory agents like microRNAs
expressed in different stages of prostate cancer are a promising opportunity to add value to
current clinical and pathological assessment methods107,108 (Fig 6).
Since each microRNA generally targets many distinct gene products, genomic variants
within the seed of microRNA could produce subtle or drastic changes in the behavior of the cell
by perturbing many different genes simultaneously29,109–111. The present study identifies, using
genome wide targeted deep sequencing, variations within the seed sequence of microRNAs in
PC3, an androgen-independent prostate cancer cell line resembling small cell neuroendocrine
carcinoma. It provides a novel understanding of the molecular mechanisms behind how signaling
pathways related to hormone resistance can be explained by altered microRNA:target interactions
due to sequence variations.
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Figure 7 Approaches to study microRNA and their impact in the clinical management of prostate
cancer. Evidence suggests that microRNAs dysregulation contributes to prostate cancer initiation and
101–103
9
metastatic progression
. Image used and modified from Josie Hayes
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Chapter 3 – Research Approach and Methods
The goal of this chapter is to introduce the research strategy and methods to perform the
computational analysis of genomic variants affecting predicted microRNA:target interactions in the
androgen-independent cell line PC3. Genomic variants include single nucleotide polymorphisms,
deletions or insertions with at least 1% mutation frequency in the population112 that have been
assigned an rs accession number in the Single Nucleotide Polymorphism database (dbSNP). The
central hypothesis of the present thesis is that a genomic variant mapping within the seed
sequence of a microRNA will have an effect on the recognition of microRNA-binding sites thus
gaining or losing microRNA:target interactions. If the microRNA:target interaction is lost, the
former target gene is expected to be upregulated. If a new microRN:target interaction is gained,
the new predicted target gene is expected to be downregulated (Figure 7).

Figure 8 Diagram representing the central hypothesis of the present thesis.

To test this hypothesis, prostate cancer cell line PC3 and prostate epithelial cells hPrEpiC
were compared to select for unique variants. Sequence capture libraries of precursor microRNAs
and genomic variants were designed by Dr. Ranjan Perera and Dr. Bongyong Lee at the Sanford
Burnham Prebys Medical Discovery Institute (Lake Nona) in collaboration with NimbleGen113.
Deep sequencing of PC3 and hPrEpiC sequence capture libraries was performed. Unique
genomic variants were filtered computationally focusing on SNPs mapping within the seed
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sequence of predicted mature microRNAs. Next steps included the computational prediction of
microRNA:target interactions of non-mutated microRNAs (termed microRNA or N) and mutated
microRNAs (termed microRNA* or M) with potential targets which 3ʹ-UTR mRNA were also
sequenced from PC3. The computational prediction of microRNA:target and microRNA*:target
interactions was performed using the rule-based algorithm context++ from TargetScanHuman
v7.1. In addition, functional enrichment analysis focused on the genes involved in the gained
interactions of microRNA*:target predictions via WebGestalt114. Gene expression microarray data
from untreated PC3 and hPrEpiC from the Gene Expression Omnibus (GEO) were retrieved and
analyzed using the affy package115 from R Bioconductor. A Fisher’s exact test via GraphPad
Prism software116 was used to assess if the observed downregulation of candidate target genes
was statistically significant. Finally, the top gained microRNA*:target interactions derived from this
study were queried in CancerMiner, an online repository of statistically recurrent microRNA:mRNA
associations in different cancer types profiled at The Cancer Genome Atlas (TCGA).

Methods
Cell Lines
Prostate cancer cell line PC3 (CRL-1435) was purchased from ATCC117. PC3 was derived
from a bone metastasis of a grade IV prostatic adenocarcinoma from a 62-year-old Caucasian
male. PC3 cells do not express AR and PSA and their proliferation is independent of androgen,
similar to small cell neuroendocrine carcinoma (SCNC)1. Genomic DNA (gDNA) from PC3 was
processed according to ATCC CRL-1435 product sheet118. Genomic DNA from human prostate
epithelial cells (hPrEpiC) was purchased from ScienCell Research Laboratories119. HPrEpiC
gDNA was prepared from early passage human prostate epithelial cells using the Qiagen Allprep
DNA/RNA Mini Kit120. The quality and purity of PC3 and hPrEpiC gDNA was tested by
spectrophotometer and gel electrophoresis by Dr. Ranjan Perera and Dr, Bongyong Lee from
Sanford Burnham Prebys Medical Discovery Institute (Lake Nona).
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Custom Target Enrichment Design and Sequence Capture Libraries
In collaboration with NimbleGen Corporation, Dr. Ranjan Perera and Dr. Bongyong Lee
from Sanford Burnham Prebys Medical Discovery Institute (Lake Nona) developed a custom
target enrichment design113 and sequence capture libraries to identify genome-wide mutations in
microRNA and their target binding sites in the 3'-UTR region of mRNAs in PC3. From the entire
genome, 1523 microRNA genes annotated in miRBase v.18 were selected to design capture
probes of precursor microRNA. For target regions along human UTRs, 67943 non-redundant
features of RefSeq genes were selected to design 3'-UTR capture regions. A constant window of
nucleotide bases upstream of ATG and a second constant window downstream of the stop codon
of each splice variant were downloaded corresponding to each RefSeq sequence. Combined
microRNA precursor sequences added up to approximately 124 Kb, and 3ʹ-UTR mRNA regions
were approximately 42 Mb. Pairs of unique probe sequences for each identified region were
determined using the SSAHA algorithm121. Precursor microRNA and 3ʹ-UTR mRNA regions were
physically enriched by hybridization following NimbleGen SeqCap Target Enrichment protocols113.
Nonspecifically bound materials were removed by washing and pull-down materials were
amplified and end-repaired for sequencing library preparation and deep sequencing. Figure 9
provides an example of the custom target enrichment design of 3ʹ-UTR mRNA and figure 10
provides an example of the custom target enrichment design of precursor microRNA regions.

Figure 9 Example of a custom target enrichment design of 3ʹ-UTR mRNA region. 42 Mb Human UTR
Design. Capture regions: 3'-UTR. Non-redundant: 67,943 features. Image source: Ranjan Perera and
Bongyong Lee.
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Figure 10 Example of a custom target enrichment design of precursor microRNA region. 124 kb
microRNA design. Capture regions: microRNA genes. miRBase version 18: 1,523 features. Image
source: Ranjan Perera and Bongyong Lee.

Deep Sequencing and Variant Calling
The detection of pre-microRNAs and variant calling analysis in PC3 was done by Dr.
Ranjan Perera, Dr. Bongyong Lee, and the Sanford Burnham Prebys Medical Discovery Institute
Bioinformatics Unit (Lake Nona) using NextGENe v2.3.1122. One limitation of this thesis was the
lack of provision of BAM and VCF files, adding the need to retrieve precursor sequences from
miRBase and to create a purpose-built VCF file by querying dbSNP. Regarding the detection of
variants in the 3ʹ-UTR of mRNAs, the same limitation was encountered by the lack of provision of
BAM and VCF files. The NextGENe v2.3.1 report of 3ʹ-UTRs included the gene ID associated to
one or more transcripts from deep sequencing. These gene IDs were key to retrieve the
representative 3ʹ-UTR sequence from the TargetScanHuman v7.1 database. The following
sections describe in detail the steps taken to overcome the above technical limitations.

Precursor microRNA Sequence Retrieval and Mature microRNA Curation
The microRNA deep sequencing NextGENe v2.3.1 report contained information of
precursor miRBase v.18 identification tags and precursor genomic coordinates based on the hum
an genome assembly version GRCh37/hg19. The identification tags allowed for the corroboration
of annotated precursor sequences in miRBase, however the newest version this database (v.21)
is based in GRCh38/hg18. Hence, genomic coordinates had to be converted from GRCh37/hg19
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to GRCh38/hg18 using the command-line version of the UCSC Genome Browser LiftOver tool123.
miRBase is the main online repository of microRNA sequence data and acts as an independent
arbiter of microRNA gene nomenclature124. Each entry in miRBase v.21124 represents a predicted
hairpin of a microRNA transcript with information on the location of the mature microRNA form.
Since each pre-microRNA can have more than one mature form either from the 5ʹ or 3ʹ end of the
precursor hairpin, the correct identification of mature sequences is calculated using a coordinates
system under miRBase v.21124 nomenclature.
Take for example hsa-mir-21b. The “hsa” indicates that it is a human microRNA, “mir”
refers to its precursor form, and “21” attributes the hairpin to the 21st family that was named in the
repository and that most likely was discovered earlier. The “b” indicates that it is related to another
microRNA probably called hsa-mir-21a. hsa-mir-21b has two mature products, named hsa-miR21b and hsa-miR-21b*. The capital R in “miR” indicates the mature sequence form of a
microRNA. In this example, miR-21b arises from the 5ʹ arm of the mir-21b hairpin, and miR-21b*
arises from the 3ʹ arm. The (star) “*” using miRBase nomenclature attributes miR-21b* as a
“minor” product, which means that miR-21b* can be found in the cell at a lower concentration
compared to miR-21b. The final nomenclature for each mature microRNA form would be hsa-miR21b-5p and hsa-miR-21b-3p, respectively. Now, consider that hsa-mir-21b is located in the
chromosome position chr5:195699401-195699497 in regards of the GRCh38/hg18 assembly.
However, miRBase reports the location of the ~22 nt long hsa-miR-21b-5p (mature microRNA)
ranging from nucleotide 14 to 36 within the pre-microRNA. In order to resolve coordinate systems
discrepancies, each pre-microRNA nucleotide has to be counted starting in position 0, to finally
get the mature microRNA sequence ranging from nucleotides 14 to 36. This is a computationally
exhaustive step which needs to be carefully automated to avoid adding or subtracting nucleotides
that will have an impact locating and retrieving the mature microRNA seed sequence. Once
genome coordinates for each mature microRNA were located, each sequence was corroborated
as a reverse (+) or complementary (-) strand to map the seed sequence. The first eight positions
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starting from the 5ʹ end were considered as the seed sequence region, and subsequently verified
by comparing to a list of microRNA families from the TargetScanHuman v7.1 database. This
reverse-engineering step was crucial for retrieving conserved microRNA family sequences with
seed-match canonical binding. Figure 11 describes the process of curating precursor hsa-mir-21b
and its corresponding mature microRNA sequences using miRBase coordinates. It represents the
integration of both miRBase v.21 and GRCh38/hg18 coordinate systems and already includes
how the seed sequence and variant change could be mapped within a predicted mature
microRNA.

Figure 11 Example of precursor hsa-mir-21b and the curation process of its predicted mature microRNA
sequences. It represents the integration of both miRBase v.21 and GRCh38/hg18 coordinate systems. The
seed sequence region is determined as the first eight nucleotides starting on the 5ʹ end verified by
comparing to a list of microRNA families from the TargetScanHuman v7.1 database. The star represents
the location of the genomic variant mapping within the seed sequence of the predicted mature microRNA
with canonical-binding.

Genomic Variant Mapping in microRNA and Candidate Selection
For the purpose of the present study, PC3 was compared to hPrEPiC to identify unique
genomic variants mapping in PC3 microRNA sequences. Changes at the precursor and mature
microRNA sequence level were done by replacing, inserting or deleting the reference nucleotide
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to the alternate allele reported by NextGENe v2.3.1. Only genomic variants with an associated
Reference SNP (RefSNP) or rs accession number from dbSNP were considered to map
statistically significant alleles with a mutation frequency of at least 1% in a population. The
definition of variant, mutation, and SNP has generated a lot of discussion and even some
contentious disagreement in the research community. However, this is important to understand
from the extent of evolutionary conservation. Mutations were originally defined as heritable
changes in phenotype and divided either as somatic (non-inherited) or germline (inherited)
changes. Variants typically arose as mutations and spread into the population resulting in more
than one form termed as "Variant/Alternative form (Allele)”. If the mutation frequency is least 1%
in a population it can termed as "Polymorphism", mostly Single Nucleotide Polymorphism (SNP).
dbSNP is the main information repository of germline and somatic variations in the human species
and assigns a RefSNP or rs accession number that appears on maps or graphic representations
of the GRCh38/hg18 human genome assembly112. In this thesis, each SNP reported by
NextGENe v2.3.1 was mapped within the precursor sequence using the chromosome location
associated to the rs accession number. If the alternate allele mapped within the region of the
potential mature microRNA, then it was verified if it also traced within the g2-g8 region of the seed
sequence.

Sequence Retrieval of 3'-UTR of mRNAs
The verification of 3'-UTR of PC3 mRNAs from deep sequencing was not possible due to
the lack of provision of BAM and VCF files. At this stage, two limitations were encountered, 1) the
proper identification of delimited 3'-UTR regions from PC3, and 2) the complexity of mapping each
potentially affected microRNA binding site without the risk of including false-positives. Using the
gene names provided by the NextGENe v2.3.1 report, the representative 3'-UTR sequences of
the reported mRNAs were downloaded in FASTA format from the TargetScanHuman v7.1
database. Figure 12 summarizes TargetScanHuman v7.1 annotation process of representative 3'UTRs using 3'-UTR profiles, and provides an example of a UTR profile for human UBE2D3. The
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annotation of each representative 3'-UTR started with the longest Gencode 3'-UTR, extended
using information from 3P-seq or other annotation sources125,126.

Figure 12 TargetScanHuman v7.1 sample UTR profile for human UBE2D3. The 3'-UTR profiles were constructed
using 3P-seq tags (with the number of tags for the 3'-UTR labeled on the y-axis on), which indicate the location
and usage of mRNA cleavage and polyadenylation sites. 3P-seq tags from multiple cell lines or tissues were
normalized to each other (to account for variable sequencing depth), and then aggregated into one consensus set
of counts. Normalized 3P-seq tags were assigned to the representative 3'-UTR of each stop codon and summed
(as indicated at the left side of the profile) to provide quantification for the usage of that stop codon. This sum
(2312 in the UTR profile shown above) also includes 5 pseudocounts added at the distal end of the Gencode
annotation. Image source: http://www.targetscan.org/docs/UTR_profiles.html

TargetScanHuman v7.1 database uses 3'-UTR profiles which represent the prevalence of
tandem 3'-UTR isoforms of differing lengths, all of which share the same stop codon126. The 3'UTR profile (red line in Figure 12) drops with each set of clustered 3P-seq tags, indicating the
fraction of transcripts that includes that segment of the 3'-UTR. Each TargetScan 3'-UTR profile
also shows the location of the most distal end of a Gencode annotation (blue vertical line with
Ensembl transcript ID in Figure 12)91. It is well known that 3'-UTR regions are shorter in
cancerous phenotypes127,128, however the decision to use representative 3'-UTR sequences in the
present thesis was mainly to create a purpose-built file of verified 3'-UTR sequences for the
computational target prediction using the context++ model from TargetScanHuman v7.1.

Target Prediction
Two computational target predictions were performed using TargetScanHuman v7.1.
Since this tool does not have an interface to query a set of mutated microRNAs, the Perl script of
the context++ model was downloaded for a custom microRNA:target prediction analysis (code
available at: http://www.targetscan.org/cgi-bin/targetscan/data_download.vert71.cgi). The first
prediction was using the set of candidate microRNAs with the alternative allele identified in the
seed sequence (from now on termed the mutated microRNA, MN, or miRNA*:target interactions).
The second prediction was using the set of candidate microRNAs without the variant (from now
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on termed the non-mutated microRNA, NN or miRNA:target interactions) using the reference
nucleotide from the NextGENe v2.3.1 report. The input files for the microRNA:target prediction
using the Perl script were: 1) the microRNA family name, species ID, and the microRNA family
seed sequence; 2) the 3'-UTRs sequences of potential targets. For the present thesis, the
purpose-built files for the computational target prediction of microRNAs with a genomic variant
mapping within the seed sequence included: 1) the microRNA family seed sequences modified
with the alternate allele in the g2-g8 positions; and 2) the representative 3'-UTR sequences
downloaded from the TargetScanHuman v7.1 database. In order to compare if the target
predictions of NN versus MN were different due to the genomic variant, the BEG Venn diagram
tool129 was used to calculate the intersection of the list of elements (MN ∩ NN) and those that
were specific to the MN or NN lists. The unique elements of miRNA:target interactions (NN – [NN
∩ MN]) were considered lost interactions. The unique elements of miRNA*:target interactions (MN
– [NN ∩ MN]) were considered gained interactions.

Functional Enrichment Analysis
Functional enrichment of a set of genes was evaluated by the WEB-based Gene SeT
AnaLysis Toolkit (WebGestalt)130,131, an integrated data mining system for the visualization and
statistical analysis of large sets of genes using functional modules within WebGestalt database114.
A hypergeometric test was performed to assess for an over-representation analysis (ORA) and
corrected for multiple hypotheses testing by the Benjamini-Hochberg method132. All p-values lower
than 0.05 were considered as significant. In addition, a gene-disease association literature search
was performed of each gene enriched for endocrine resistance and endocrine and other factorregulated calcium reabsorption categories.

Gene Expression Analysis
The public Gene Expression Omnibus (GEO) repository was systematically searched for
untreated samples of prostate cancer cell line PC3 and for human prostate epithelial cells
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(hPrEpiC) with the focus on a single DNA microarray platform to obtain easily compared data. For
this purpose, the hgu133plus2 human DNA array (Affymetrix Inc., Santa Clara, CA, USA)
containing 20,535 DNA probes was selected. Three samples of untreated PC3 (GSM86079,
GSM86080, GSM86081) and two samples of human prostate epithelial cells (GSM1095876,
GSM1060763) were identified on the hgu133plus2 platform. CEL data files were retrieved from
the public GEO repository and processed using a robust multi-array (RMA)133 normalization
protocol with the affy package115 in R Bioconductor. Annotations and attributes were imported
from the hgu133plus2 annotation files provided by Affymetrix Inc. (Santa Clara, CA, USA). New
predicted target genes from microRNAs*:target gained interactions were corroborated to have an
associated Entrez Gene ID corresponding to any of the 20,535 genes assessed by the
hgu133plus2 platform. Overexpressed and underexpressed target genes were assessed using
the limma package134. Differentially expressed genes (DEG) of PC3/hPrEpiC were plotted using a
log2 fold change (log2FC) and a p-value < 0.01

Statistical Analysis
A Fisher’s exact test was applied to each set of new predicted microRNA*:target
interactions to assess if the observed gene expression changes were statistically significant.
Contingency tables were built using Prism v7 (GraphPad Software, La Jolla, CA, USA) and pvalues lower than 0.05 were considered as significant. In addition, the non-parametric test
Kruskal-Wallis was performed using R in order to evaluate if there were statistically significant
differences between groups of PC3 expressed genes assessed by the hgu133plus2 platform.
These groups were organized as follows: group A included all PC3 genes inquired by the
Affymetrix hgu133plus2 microarray minus the total number of genes of gained and lost predicted
microRNA:target interactions from mutated and non-mutated microRNAs (total hgu133plus2
genes – genes from the MN list + genes from the NN list). Group B included all gained predicted
microRNA*:target interactions (genes from the MN list). Group C included all lost predicted
microRNA:target interactions (genes from NN list). Group D included the predicted
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microRNA:target interactions that remained the same regardless of the genomic variant affecting
the seed sequence (genes from the MN ∩ NN lists). Groups A, B, C, D data are available at:
https://github.com/microRNA-PCa/PC3/

under

the

branch

names

data.A_BoxPlot,

data.B_BoxPlot, data.C_BoxPlot, and data.D_BoxPlot. For the Kruskal-Wallis test, six
comparisons were performed using one degree of freedom (df = 1), where p-values lower than
0.05 were considered as significant.

Recurrent microRNA-mRNA Expression Associations from TCGA
Top candidate microRNA*:target interactions from TargetScanHuman v7.1 which genes
were enriched for endocrine resistance and endocrine and other factor-regulated calcium
reabsorption from WebGestalt, were queried against the CancerMiner database14. CancerMiner is
an online resource encompassing a statistical method used to evaluate recurrence of microRNAmRNA expression association (REC) across cancer types from The Cancer Genome Atlas
(TCGA). Figure 13 provides an overview of CancerMiner statistical approach135. In individual
cancer types, pairwise miRNA-mRNA relationships are evaluated using a multivariate linear
model, which also factors in variation (noise) in mRNA expression induced by changes in DNA
copy number and promoter methylation at the mRNA gene locus. Associations are rank
transformed in individual cancer types, and the method subsequently evaluates the null
hypothesis that no association exists between the miRNA-mRNA pair in all cancer types14.
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Figure 13 CancerMiner an online tool based on REC, a statistical approach evaluating recurrence of
microRNA-mRNA expression association across cancer types from The Cancer Genome Atlas (TCGA).
14
Image used from A. Jacobsen et al .
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Chapter 4 – Results
Summary
In this chapter, the outcomes of the study are thoroughly described starting with variant
mapping and microRNA* selection for further computational target predictions. miR-3161*-5p,
miR-3620*-5p, miR-1178*-5p, miR-4804*-5p, miR-449c*-3p with a SNP in the g2-g8 position of
the seed sequence gained 643 new interactions with genes sequenced from PC3. We provide
evidence that alternative alleles mapping within the seed sequence of microRNA do affect the
prediction of microRNA*:target interactions, thus losing or gaining new seed-match canonical
binding. After functional enrichment of new targets, ABCB11, CDKN1B, NOTCH2, SHC4,
CCND1, SP1, ADCY2 were associated with endocrine resistance. In addition, ATP1A2, ESR1,
PRRKCB, AP2B1, SLC8A1 were associated with endocrine and other factor regulated calcium
reabsorption. A gene-disease association literature search was performed for each of the
aforementioned genes in order to understand if they have implicated in cancer, where CDKN1B,
NOTCH2, CCND1 have been associated to prostate cancer progression. Microarray gene
expression results showed that few predicted microRNA* targets were underexpressed in
untreated PC3 samples versus prostate epithelial cells from the GEO database. Hence, a Fisher’s
exact test was performed to assess the frequency of observed underexpressed genes per
candidate microRNA*. Only miR-4804*-5p was statistically significant with TNKS and GUCY1A3
as target genes. However, neither TNKS, nor GUCY1A3 were part of the group of genes enriched
for endocrine resistance. Next steps included comparisons between groups of genes subject to
non-mutated microRNA and mutated microRNA* regulation using a Kruskal-Wallis non-parametric
test. The effect of miR-3161*-5p, miR-3620*-5p, miR-1178*-5p, miR-4804*-5p, and miR-449c*-3p
cannot be predicted solely with this indirect experimental approach. For that reason, the
assessment of recurrent pairwise microRNA-mRNA expression associations was performed using
CancerMiner, an online tool from The Cancer Genome Atlas (TCGA) based on a multivariate
linear model and rank transformations. Results indicate that miR-3161*-5p and CDKN1B are
strong candidates for experimental validation in the context of prostate cancer cell line PC3.
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Deep Sequencing of pre-microRNA in PC3 and Variant Calling
The NextGENe v2.3.1 report of pre-microRNA deep sequencing of PC3 contained the precursor accession number in miRBase
v.18, which allowed for the retrieval of precursor sequences from miRBase v.21. In addition, the report included the reference nucleotide
(Ref nt), the mutation call (PC3 Mutation Call), and the rs accession number associated to a SNP within dbSNP (SNP db_xref), allowing for
the retrieval of genomic coordinates for each SNP unique to PC3 from the aforementioned database. Table 1 provides a sample of the
NextGENe v2.3.1 report and exemplifies genomic variants mapping within precursor microRNAs in PC3 that were not shared with human
prostate epithelial cells.
Index
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Precursor
miRNA

hsa-mir3620
hsa-mir1307
hsa-mir4481
hsa-mir202
hsa-mir604
hsa-mir604
hsa-mir3161
hsa-mir4300

Precursor
Accession

MI0016011
MI0006444
MI0016842
MI0003130
MI0003617
MI0003617
MI0014191
MI0015831

Table 1 NextGENe v2.3.1 report sample of pre-microRNA deep sequencing and variant calling. A phred-score of QV >30 was considered for all SNP
calls.
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Unique Genomic Variants in microRNA Seed Sequence
The hypothesis of the present thesis is that a genomic variant mapping within the seed
sequence of a microRNA will have an effect on the recognition of microRNA-binding sites thus
gaining or losing microRNA:target interactions. Unique genomic variants in PC3 were filtered from
the NextGENe v2.3.1 report by mapping within precursor sequences using genome coordinates
from the GRCh38/hg18. From 52 pre-microRNAs captured in the enrichment design library, 27
genomic variants were unique to PC3 in comparison to human prostate epithelial cells. Only 18
unique variants mapped within predicted mature microRNA sequences, where 12 SNPs mapped
within the mature microRNA derived from the 5ʹ end of the reported precursor (-5p) and 6 within
reverse/complementary strands derived from the 3ʹ end of reported precursors (-3p).
The molecular mechanism of microRNA:mRNA interaction includes the Argonaute protein,
which organizes the guide RNA geometry in a way that positions g2–g7 of the seed sequence end
in a pre-helical form. This structural configuration determines whether RISC binds, or binds and
cleaves to the target mRNA27,79,136. In addition, based on seed-pairing categorization it is known
that most microRNA with canonical binding sites in the 3'-UTR in mRNA are functional. With this
rationale, only genomic variants mapping within the g2-g8 positions of the seed sequence were
considered for the selection of microRNA candidates for target prediction. A total of 5 single
nucleotide polymorphisms with an associated RefSNP mapped within the g2-g8 positions of the
seed sequence region of miR-3620, miR-3161, miR-1178, miR-4804, and miR-449c. Figure 14
provides a schematic representation of the mapping process of genomic variants from the
precursor sequence level to the seed sequence region of predicted mature microRNAs in PC3.
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Figure 14 Schematic representation of the process of mapping unique genomic variants of PC3 at the
precursor, mature microRNA, and seed sequence sequence level.

The five candidate microRNA sequences were retrieved from miRBase v.21 and verified to
have an association to a confidently annotated microRNA family in TargetScanHuman v7.1
database. The reported alternative alleles identified from deep-sequencing were mapped and
changed within each mature microRNA candidate sequence as summarized in Table 2.

microRNA

Sequence 5′-3′

dbSNP

Variant call

Seed
sequence
position

miR-3620-5p

gugggCugggcugggcugggcc

rs2070960

C→T

g6

miR-3161-5p

cugauaa--gaacagaggcccagau

rs35834266

insA

g8

miR-1178-5p

cagggucAgcugagcaug

rs7311975

T→G

g8

miR-4804-5p

uuggaCgguaagguuaagcaa

rs266435

C→G

g6

miR-449c-3p

uUgcuaguugcacuccucucugu

rs35770269

A→T

g2

Table 2 Seed sequences of normal and mutated microRNA are shown in this table with the corresponding
alternative allele insertion reported from PC3 deep-sequencing experiments.
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Target Prediction
Two computational target predictions were performed using the Perl script of the
context++ algorithm from TargetScanHuman v7.1. Each of the mutated microRNAs was termed
with a * (star) to differentiate the nomenclature between mutated microRNA (microRNA*) and
non-mutated microRNA. The first prediction was using miR-3620*-5p, miR-3161*-5p, miR-1178*5p, miR-4804*-5p, and miR-449c*-3p with the reported alternate allele mapping within the seed
sequence from the deep-sequencing analysis as summarized in Table 2. The output file of this
first prediction was renamed miRNA*:target interactions or MN list.
The second target prediction included miR-3620-5p, miR-3161-5p, miR-1178-5p, miR4804-5p, and miR-449c-3p with the reported reference nucleotide from the deep-sequencing
analysis as summarized in Table 2. The output file of the second prediction was termed
miRNA:target interactions or NN list. Both computational target predictions were constrained to
only assess for canonical binding sites. Finally, both output files were compared (MN list vs NN
list) where: 546 interactions were identified as unique elements of the NN list and considered lost
interactions; 643 interactions were identified as unique elements of the MN list and considered
gained interactions; and 15 interactions were identified as shared elements between the MN and
NN lists and were considered as unchanging interactions. Figure 15 provides the Venn diagram of
the comparison of the predicted microRNA:target interactions (NN elements) versus
microRNA*:target interactions (MN elements). TargetScanHuman v7.1 predictions results
summarized as MN and NN lists are available at https://github.com/microRNA-PCa/PC3
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Nomenclature:
•
•
•
•

N first position: non-mutated microRNA
N second position: non-mutated 3′-UTR mRNA
M first position: mutated microRNA
N second position: non-mutated 3′-UTR mRNA

Figure 15 Venn diagram summarizing the 546 lost interactions (NN), 643 gained interactions (MN), and 15
interactions that were still predicted for both mutated and non-mutated microRNAs (MN ∩ NN).

Functional Enrichment Analysis
A functional enrichment analysis was performed on gained target genes (from predicted
microRNA*:target interactions) and lost target genes (from predicted microRNA:target
interactions). Both gene sets were queried for an over-representation analysis (ORA) using
WebGestalt. Inherent limitations of the ORA method include the mandatory selection of a
threshold in the analysis of gene subsets and the statistical assumption that all genes are equal,
which might result in loss of information. From 546 predicted genes interacting with non-mutated
microRNA, only 510 had an associated Entrez gene ID which was used by WebGestalt for the
ORA analysis (Supplementary Table 1). From 643 predicted genes interacting with mutated
microRNA*, only 598 had an associated Entrez gene ID which was used by WebGestalt for the
ORA analysis. As multiple tests were carried out simultaneously, a gene was considered to be
over-represented if the p-value was < 0.05 after the Benjamini-Hochberg adjustment. No
enrichment was found for miR-449c*-3p gained targets, probably due to the small number of
candidate targets available from the computational prediction of miR-449c*-3p:target interactions.
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Table 3 summarizes the ORA results of enriched genes from gained microRNA*:target
interactions.

Table 3 Summary of the functional enrichment analysis of gained target genes. 598 Entrez gene IDs out
643 predicted genes were enriched using a hypergeometric analysis. These set of genes have been
predicted to interact with miR-3620*-5p, miR-3161*-5p, miR-1178*-5p, and miR-4804*-5p due to an
alternate allele in the seed sequence region. The first column ID corresponds to the KEGG pathway ID
annotated in the human species (hsa), the second column corresponds to the enrichment category, and
the third column corresponds to the number of genes that have been associated to each enrichment
category.

Seven genes were enriched for endocrine resistance with a p-value < 1.28e-02: ABCB11,
CDKN1B, NOTCH2, SHC4, CCND1, SP1, ADCY2. And five genes were enriched for endocrine
and other factor-regulated calcium reabsorption with a p-value < 1.64e-02: ATP1A2, ESR1,
PRRKCB, AP2B1, SLC8A1. A genes-disease association literature search was performed for
each of the aforementioned genes in order to identify which genes have been implicated in
cancer. From the literature search CDKN1B, NOTCH2, CCND1 were identified to participate in
prostate cancer progression. Table 4 summarizes the gene enrichment analysis results organized
by microRNA*:target and subdivided by enrichment category. In addition, a brief description of the
gene-disease association is included with its corresponding literature reference.
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microRNA

Enrichment category

Predicted targets

Disease Association

Ref

Endocrine resistance

ABCB11

Liver diseases such as
cholestasis
Multiple endocrine
neoplasia, prostate cancer,
breast cancer
Angiogenesis and
metastasis, prostate cancer
Urethral structure and male
reproductive organ cancer
Migraine and familial
hemiplegic

137,138

miR-3161*-5p

CDKN1B

NOTCH2
SHC4
ATP1A2

146,147

148–150

ESR1

Breast, endometrial, and
ovarian cancer

67,151–153

Endocrine resistance

CCND1

Multiple myeloma, breast
and prostate cancer
Huntington disease, gastric,
breast, and colorectal
cancer
Adrenal gland disease and
colorectal cancer
Glioblastoma

142,154–156

Ataxia telangiectasia,
rhabdomyosarcoma
Long qt syndrome, heart
diseases

165–167

SP1

miR-4804*-5p

143–145

Endocrine and other
factor-regulated calcium
reabsorption

miR-3620*-5p

miR-1178*-5p

139–142

Endocrine resistance

ADCY2

Endocrine and other
factor-regulated calcium
reabsorption
Endocrine and other
factor-regulated calcium
reabsorption

PRKCB

AP2B1
SLC8A1

157–160

161,162

163,164

168,169

Table 4 Gene enrichment analysis results of genes predicted to be targets of mutated microRNAs. Genedisease associations include different cancer types where CDKN1B, NOTCH2, and CCND1 have been
implicated in prostate cancer progression.

Gene Expression Analysis
To further assess the hypothesis of the present thesis, if genomic variants significantly
affect the seed sequence of microRNA*, then the expression of genes associated to endocrine
resistance should be perturbed in PC3 versus prostate epithelial cells (EPIC). In other words,
gained targets are anticipated to be downregulated given the microRNA*-mediated model for
gene expression regulation at the post-transcriptional level. Microarray gene expression analyses
of predicted new targets were performed using three untreated PC3 samples and 2 human
prostate epithelial cells samples from the GEO database (see Chapter 3 Methods for accession
number). Differentially expressed genes (DEG) were assessed by comparing prostate cancer cell
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line PC3 versus human prostate epithelial cells (hPrEpiC or EPIC). Gene expression analysis
results are displayed in figure 16 using a volcano plot with a p-value < 0.01 and a log2 Fold
Change. The color coding indicates the overexpression of 374 genes (red) and the
underexpression of 152 genes (green) in prostate cancer cell line PC3. The list of overexpressed
genes is available at https://github.com/microRNA-PCa/PC3/blob/master/DEG_over and the list of
underexpressed

genes

is

available

at

https://github.com/microRNA-

PCa/PC3/blob/master/DEG_under

Figure 16 Differentially expressed genes (DEG) from PC3-EPIC microarray data using the Affymetrix
hgu133plus2 platform, where 374 genes were overexpressed (red) and 152 genes were underexpressed
(green).
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From 643 predicted microRNA*:target interactions, a total of 592 Entrez gene IDs were
assessed by the hgu133plus2 microarray platform. From those 592 Entrez gene IDs, only few
genes had expression changes according to the microRNA*:target model. Table 5 provides a
summary of predicted new targets from TargetScanHuman v7.1 by microRNA* and the number of
observed underexpressed genes from those predicted interactions.

Mutated
microRNA*
miR-3161*-5p
miR-3620*-5p
miR-1178*-50
miR-4804*-5p
miR-449c*-3p
Total new interactions

TargetScanHuman v7.1
(predicted gained interactions)
220
90
122
156
55
643

Affymetrix hgu133plus2 platform
(underexpressed genes of
predicted gained interactions)
2
2
3
4
1
12

Table 5 Summary of predicted new targets by TargetScanHuman v7.1 and the number of observed
underexpressed genes from those predicted interactions in the DEG Affymetrix hgu133plus2 data.

The small amount of observed changes was most likely due to the low number of
untreated PC3 and human prostate epithelial cell samples in the GEO database. A Fisher’s exact
test was needed to translate the frequency of perturbed targets into a p-value to assess for
statistically significance.

Statistical Analysis
A Fisher’s exact test was used to assess if the observed gene expression changes of
gained targets were statistically significant (p-value < 0.05). For each microRNA* a contingency
table was built using the Prism v7 software116 with the values provided in table 5. For example, the
contingency table for miR-4804*-5p has 156 predicted interactions from TargetScanHuman
(column A) where only 4 genes are observed to be underexpressed assuming that they are
downregulated due to miR-4804*-5p (column B). The hgu133plus2 platform inquires a total of
20,535 genes (column A) where 152 genes are observed to be underexpressed in PC3 (column
B). The Fisher’s exact test p-value was 0.0324, meaning that the observed underexpressed
genes of miR-4804*-5p:target interactions are statistically significant (Table 6).
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Data analyzed
Containing binding sites
All genes in microarray
Total
p-value
One- or two-sided

Column A

Column B

156
20535
20691

4
152
156

Total
160
20687
20847

0.0324
Two-sided

Statistically significant
(p < 0.05)?

Yes

Table 6 Contingency table miR-4804*-5p predicted targets. The observed underexpressed genes of miR4804*-5p:target interactions are statistically significant.

Contingency tables were built for each microRNA* using the Prism v7 software and results were
as follows:

Table 7 recapitulates the Fisher’s exact test results for miR-3161*-5p with a p-value of 0.6802,
meaning that the observed underexpressed genes of miR-3161*-5p:target interactions are not
statistically significant.
Data analyzed
Containing binding sites
All genes in microarray
Total
p-value
One- or two-sided
Statistically significant
(p < 0.05)?

Column A
220
20535
20755
0.6802
Two-sided

Column B
2
152
154

Total
222
20687
20909

No

Table 7 Contingency table miR-3161*-5p predicted targets. The observed underexpressed genes of miR3161*-5p:target interactions are not statistically significant.

Table 8 recapitulates the Fisher’s exact test results for miR-3620*-5p with a p-value of 0.1489,
meaning that the observed underexpressed genes of miR-3620*-5p:target interactions are not
statistically significant.
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Data analyzed
Containing binding sites
All genes in microarray
Total
p-value
One- or two-sided
Statistically significant
(p < 0.05)?

Column A
90
20535
20625
0.1489
Two-sided

Column B
2
152
154

Total
92
20687
20779

No

Table 8 Contingency table miR-3620*-5p predicted targets. The observed underexpressed genes of miR3620*-5p:target interactions are not statistically significant.

Table 9 recapitulates the Fisher’s exact test results for miR-1178*-5p with a p-value of 0.0668,
meaning that the observed underexpressed genes of miR-1178*-5p:target interactions are not
statistically significant.
Data analyzed
Containing binding sites
All genes in microarray
Total
p-value
One- or two-sided
Statistically significant
(p < 0.05)?

Column A
122
20535
20657
0.0668
Two-sided

Column B
3
152
155

Total
125
20687
20812

No

Table 9 Contingency table miR-1178*-5p predicted targets. The observed underexpressed genes of miR1178*-5p:target interactions are not statistically significant.

Table 10 recapitulates the Fisher’s exact test for miR-449c*-3p with a p-value 0.3398, meaning
that the observed underexpressed genes from miR-449c*-3p:target interactions are not
statistically significant.
Data analyzed
Containing binding sites
All genes in microarray
Total
p-value
One- or two-sided
Statistically significant
(p < 0.05)?

Column A
55
20535
20590
0.3398
Two-sided

Column B
1
152
153

Total
56
20687
20743

No

Table 10 Contingency table miR-449c*-3p predicted targets. The observed underexpressed genes of miR449c*-3p:target interactions are not statistically significant.
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Finally, only the observed underexpressed genes of miR-4804*-5p:target interactions were
statistically significant. The genes predicted to be interacting with miR-4804*-5p and
underexpressed in PC3 were: TNKS, a poly (ADP-ribose) polymerase involved in the regulation of
Wnt/beta-catenin signaling and that has been implicated in the pathology of various forms of
cancer170. And GUCY1A3, a paralog gene of GUCY1A1, which is a soluble guanylate cyclase that
catalyzes the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate, and that has been
implicated in progressive cerebral angiopathy171. However, neither TNKS, nor GUCY1A3 were
enriched for endocrine resistance via WebGestalt.
In addition, two box plots were built using log2 ratios and p-values to compare the
expression of all PC3 genes assessed by the hgu133plus2 platform versus the expressed genes
of untreated PC3 samples involved in the 643 gained interactions, 546 lost interactions, and 15
remaining interactions despite the genomic variant affecting the 5 candidate microRNAs* seed
sequence. Figure 17 summarizes the aforementioned groups, which were organized as follows:
group A included all genes inquired by the hgu133plus2 microarray minus the total number of
genes of gained and lost predicted microRNA:target interactions from mutated and non-mutated
microRNAs (total hgu133plus2 genes – genes from the MN list + genes from the NN list). Group B
included all gained predicted microRNA*:target interactions (genes from the MN list). Group C
included all lost predicted microRNA:target interactions (genes from NN list). Group D included
the predicted microRNA:target interactions that remained the same regardless of the genomic
variant affecting the seed sequence (genes from the MN ∩ NN lists). It was not apparent from the
box plots that the average expression levels of gained targets were lower than the total average
expression, and this could not be deduced either by comparing different quartile distributions as
shown in the box plots.
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Figure 17 Gene expression analysis using box plots to compare the expression of all PC3 genes
assessed by the hgu133plus2 platform (Group A) versus the expressed genes of untreated PC3 samples
involved in the 643 gained interactions (Group B), 546 lost interactions (Group C), and 15 remaining
interactions (Group D) despite the genomic variant affecting the 5 candidate microRNAs* seed sequence.
It was not apparent from the box plots that the average expression levels of gained targets were lower
than the total average PC3 gene expression.

Hence, the Kruskal-Wallis non-parametric test was used to determine if there were
statistically significant differences between groups. Table 11 summarizes the Kruskal-Wallis test
results, where only the comparison of Group A vs Group B, and the comparison of Group A vs
Group C were statistically significant. In other words, Group A is not subject to the present study
five candidate microRNAs regulation, while Group B is subject to miR-3620-5p, miR-3161-5p,
miR-1178-5p, miR-4804-5p, and miR-449c-3p and Group C is subject to miR-3620*-5p, miR3161*-5p, miR-1178*-5p, miR-4804*-5p, and miR-449c*-3p. These results are consistent with the
microRNA-gene expression regulation model, despite the genomic variant in the seed region.
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Comparison
Group A vs Group B
Group A vs Group C
Group A vs Group D
Group B vs Group D
Group B vs Group C
Group C vs Group D

Kruskal-Wallis
chi-squared (H)
60.915
30.332
3.8363
0.80014
1.9647
1.5744

p-value
by group
5.959e-15
3.641e-08
0.05015
0.3711
0.161
0.2096

Statistically significant
(p < 0.05)?
Yes
Yes
No
No
No
No
Degrees of freedom (df = 1)

Table 11 Kruskal-Wallis test results. Only the comparison of the medians of all PC3 expressed genes
inquired by the hgu133plus2 platform (Group A) versus the expressed genes of untreated PC3 samples
involved in the 643 gained interactions (Group B) and 546 lost interactions (Group C) were statistically
significant.

Recurrent microRNA-mRNA Expression Associations from TCGA
The small number of untreated PC3 and prostate epithelial cell samples available at the
GEO database, and the limitation of not having pairwise microRNA-mRNA expression data in the
same physiological conditions made it difficult to garner meaningful information to support
functional implications of computationally predicted microRNA*:target interactions. For that
reason, miR-3620*-5p, miR-3161*-5p, miR-1178*-5p, miR-4804*-5p, and miR-449c*-3p and the
alternate alleles from PC3 deep-sequencing reports were queried using The Cancer Genome
Atlas (TCGA) Data Portal interphase. None of the candidate microRNAs or genomic variants
retrieved any results, probably because these microRNAs have been newly annotated based on
their miRBase nomenclature, their low abundance in different profiled tumor types at TCGA, or
lost information due to the lack of uniformity in data generation in TCGA172.
However, Jacobsen et al. developed a statistical method to evaluate recurrence of miRNAmRNA expression association across ten epithelial cancer types from TCGA. This method
considers pairwise miRNA-mRNA relationships in individual cancer types and evaluates these
relationships using a multivariate linear model, which also factors in variation (noise) in mRNA
expression induced by changes in DNA copy number and promoter methylation at the mRNA
gene locus. Associations are rank transformed in individual cancer types, and the method
44

subsequently evaluates the null hypothesis that no association exists between the miRNA-mRNA
pair in all cancer types14.
The twelve candidate microRNA*:target interactions summarized in Table 4, were queried
against the CancerMiner database. Only the relationship of miRNA-3161:CDKN1B was retrieved
as a recurrent expression association in uterine corpus endometrial carcinoma (UCEC) with an
association score (REC) by individual cancer type of -0.44 and a p-value of 0.366. Although the
REC score did not provide a very strong association at the individual level, the result supports that
miRNA-3161:CDKN1B interaction is likely to be functionally relevant in the cancer context.
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Chapter 5 – Discussion and Future Directions
The present thesis systematically analyzes microRNA seed polymorphisms in prostate
cancer cell line PC3 and infers possible effects on microRNA:target interactions with functional
implications relevant in the cancer context. MiR-3620*-5p, miR-3161*-5p, miR-1178*-5p, miR4804*-5p, and miR-449c*-3p with a SNP mapping in the g2-g8 seed sequence region gained 643
computationally predicted microRNA*:target interactions with canonical binding features. After
functional enrichment, seven new targets were genes associated with endocrine resistance (pvalue < 1.28e-02) and five genes were associated to endocrine and calcium reabsorption (p-value
< 1.64e-02) categories. At least three genes involved in new microRNA*:target interactions
(CDKN1B, NOTCH2, CCND1) are consistent with current gene-disease association literature
related to their downregulation in prostate cancer progression. These results support the central
hypothesis of this thesis, as microRNA gene variability interferes with the complementarity of
microRNA:mRNA, perturbing target recognition leading to the downregulation of genes associated
to disease susceptibility.
One of the biggest challenges for computational studies is to predict a phenotype as
accurately as possible and to reconcile results with high-throughput experimental approaches
such as microarrays, RNA-seq or AGO-PAR-CLIP in case of microRNA:target interactions. In
order to provide evidence of gene expression changes due to mutated microRNAs, a microarray
expression analysis of PC3 versus prostate epithelial cells was performed using untreated
samples using the hgu133plus2 platform from the GEO database. A low number of expected
targets were observed to be underexpressed in PC3, probably due to the small sample size of
data sets available at GEO. Hence, a Fisher’s exact test was used to translate the frequency of
perturbed targets into a p-value for the assessment of statistically significance. Only microRNA4804*-5p observed underexpressed targets TNKS and GUCY1A3 were statistically significant (pvalue < 0.05). However, neither TNKS nor GUCY1A3 were in the group of genes previously found
to be enriched for endocrine resistance via WebGestalt. This indirect method assessed the effect
46

of microRNAs* over predicted target expression assuming the untreated PC3 samples have
enough microRNA expression abundance for repression to be detectable91. Due to the lack of
pairwise microRNA and gene expression data in PC3, we cannot completely predict the effect of
our candidate microRNAs* solely with this indirect experimental approach.
Furthermore, four groups of genes assessed by the hgu133plus2 platform were organized
based on their predicted interactions with non-mutated microRNA and mutated microRNA. A
Kruskal-Wallis non-parametric test was performed in order to assess for statistical significance
between groups, where Group A (genes not subject to the regulation of the present study
microRNA candidates) versus Group B (genes regulated by candidate non-mutated microRNAs),
and Group A versus Group C (genes regulated by candidate mutated microRNAs) showed
differences regarding group medians. It would have been interesting to observe statistical
significance comparing Group B versus Group C, but with AGO-PAR-CLIP experimental data to
assess the effect of SNPs affecting the seed region of miR-3620*-5p, miR-3161*-5p, miR-1178*5p, miR-4804*-5p, and miR-449c*-3p.
A

third

statistical

assessment

was

performed

by

querying

twelve

candidate

microRNA*:target interactions summarized in Table 4 against the CancerMiner database.
CancerMiner is an online tool from The Cancer Genome Atlas (TCGA) which evaluates
recurrence of miRNA-mRNA expression association across ten epithelial cancer types from
TCGA135. This method considers pairwise miRNA-mRNA relationships in individual cancer types
and evaluates these relationships using a multivariate linear model. Associations are rank
transformed in individual cancer types, and subsequently tested with the null hypothesis that no
association exists between the miRNA-mRNA pair in all cancer types14. Only the relationship of
miRNA-3161:CDKN1B was retrieved as a recurrent expression association in uterine corpus
endometrial carcinoma (UCEC) with an association score (REC) by individual cancer type of -0.44
and a p-value of 0.366. Although the REC score did not provide a very strong association at the
individual level, the result supports that miRNA-3161:CDKN1B interaction is likely to be
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functionally relevant in different cancer types. In the context of this study, results suggest that
CDKN1B dysregulation by miR-3161*-5p would be leading to PC3 proliferation due to the lack of
cell cycle arrest from phase G1 to S (Figure 18). CDKN1B (p27Kip1) is a member of the cip/kip
family of cyclin-dependent kinase inhibitors that phosphorylate the retinoblastoma protein (Rb)
through binding to cyclin-cdk complexes: cyclin E-cdk2; cyclin A-cdk2; and cyclin D-cdk4173,174.
Failure of cell cycle arrest secondary to alterations in cdk inhibitor expression has been implicated
in prostate cancer progression175,176 and luminal breast cancer (LBC)177. CDKN1B has been found
to be mutated in few other neoplasia such as small intestine neuroendocrine tumors, a rare
carcinoma arising from endocrine precursor cells in which CDKN1B represents the most
frequently mutated gene139. In addition, CDKN1B germline mutations have been also proposed to
be the cause of Multiple Endocrine Neoplasia type 4 (MEN4), an autosomal dominant disorder
characterized by the occurrence of tumors in endocrine glands178.
Prostate cancer cell line PC3 has been described in thousands of publications over the
last four decades and has shown to share features with prostatic small cell neuroendocrine
carcinomas (SCNC) with the implication that molecular mechanisms and therapeutic efficacies
observed with PC3 cells are likely applicable to SCNC1. Prostatic small cell neuroendocrine
carcinoma is a variant form of prostate cancer often characterized by an aggressive course with a
poor response to conventional androgen deprivation therapy (ADT), consistent with the lack of the
androgen receptor in prostatic small cell carcinoma (SCC)2. In some men treated with ADT,
development of small cell carcinoma might represent the “escape” of a subpopulation of hormoneindependent cells resulting from the selective pressure of hormonal therapy3. This phenomenon
has been observed in other hormone-driven cancer types such as human basal like breast cancer
cells with the downregulation of p27Kip1 which abrogates antiestrogen-mediated cell cycle arrest179.
Hence, the suggestion of CDKN1B dysregulation by miR-3161*-5p might go beyond the
idiosyncrasy of the PC3 cell line, but rather an interesting future direction to investigate prostate
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cancer patients with small cell neuroendocrine carcinoma rendering to an adverse disease
outcome due to uncontrolled cell proliferation.

Figure 18 CDKN1B dysregulation by miR-3161*-5p might lead to PC3 proliferation due to the lack of cell
cycle arrest from phase G1 to S. Molecular mechanisms and therapeutic efficacies observed with PC3 cells
are likely applicable to small cell neuroendocrine carcinoma (SCNC), a variant form of prostate cancer often
characterized by an aggressive course with a poor response to conventional androgen deprivation therapy
(ADT). The pathway from CDKN1B to E2DFP was obtained from KEGG.
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Copyright releases of all previously published figures that have been used in this thesis, either
unmodified or without substantial modification, have been requested/obtained.
These are kept in: https://github.com/microRNA-PCa/PC3
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Appendix
Supplementary Table 1:
From 546 predicted genes interacting with non-mutated microRNA, only 510 had
associated Entrez gene IDs which were considered by WebGestalt for the ORA analysis. Table 4
summarizes the ORA results of genes from gained microRNA:target interactions.

Summary of the enriched categories of 510 Entrez gene IDs out 546 predicted genes interacting with
miR-3620-5p, miR-3161-5p, miR-1178-5p, miR-4804-5p, and miR-449c-3p without a SNP mapping within
the seed sequence region. The first column ID corresponds to the KEGG pathway ID annotated in the
human species (hsa).
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